[:pb]Authors: Antinarelli, L. M. R. ; De Souza, M. V. N.; Coelho, E. A. F. ; Lima, W. P. ; Coimbra, E. S.
Source: Sociedade Brasileira De Medicina Tropical, v. 53, p. 1-5, 2020
Publisher: Revista da Sociedade Brasileira de Medicina Tropical
Abstract
Introduction: The drugs currently available for leishmaniasis treatment have major limitations.
Methods: In vitro and in vivo studies were performed to evaluate the effect of a quinoline derivative, Hydraqui (7-chloro-4-(3-hydroxy-benzilidenehydrazo)quinoline, against Leishmania amazonensis. In silico analyses of absorption, distribution, metabolism, excretion, and toxicity (ADMET) parameters were performed.
Results: Hydraqui showed significant in vitro anti-amastigote activity. Also, Hydraqui-treated mice exhibited high efficacy in lesion size (48.3%) and parasitic load (93.8%) reduction, did not cause hepatic and renal toxicity, and showed appropriate ADMET properties.
Conclusions: Hydraqui presents a set of satisfactory criteria for its application as an antileishmanial agent
Keywords: leishmania amazonensis, quinoline, chemotherapy, cutaneous leishmaniasis, toxicity
Document Type: Research Article
DOI: 10.1590/0037-8682-0091-2020
Publication date: 14 de abril de 2020[:]
